Pfizer Spending Twice As Much On Selling Than Research? |
| December 10, 2019 | December 2019 Bond Updates |
|
Pfizer (NYSE: PFE) spends nearly twice the money on selling, general & administrative (SG&A) expenses than it does on research & development (R&D). SG&A Accounted for 34% of the company’s total expenditure in 2018, while it was 19% for R&D.This can partly be attributed to the promotional expenses... |
| View more at: https://www.forbes.com/sites/greatspeculations/2019/12/09/pfizer-spending-twice-as-much-on-selling-than-research/ |
| Related News |